GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Interest Expense

ADC Therapeutics (ADC Therapeutics) Interest Expense : $-48.97 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ADC Therapeutics's interest expense for the three months ended in Mar. 2024 was $ -12.50 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-48.97 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ADC Therapeutics's Operating Income for the three months ended in Mar. 2024 was $ -33.37 Mil. ADC Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $ -12.50 Mil. ADC Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


ADC Therapeutics Interest Expense Historical Data

The historical data trend for ADC Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Interest Expense Chart

ADC Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Expense
Get a 7-Day Free Trial -0.16 -4.93 -18.34 -36.73 -46.33

ADC Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.29 -15.86 -12.94 -7.68 -12.50

ADC Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-48.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ADC Therapeutics  (NYSE:ADCT) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ADC Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $-12.50 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-33.37 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $122.90 Mil.

ADC Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

ADC Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


ADC Therapeutics (ADC Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.